Introduction: This study aimed at estimating the incidence of pregnancy after antiretroviral therapy (ART) initiation in 8 West African countries over a 10-year period.
INTRODUCTION
Women of reproductive age constitute the largest population affected by HIV infection in sub-Saharan Africa. 1 The wide availability of antiretroviral therapy (ART) in African settings has considerably decreased morbidity and mortality of many women living with HIV, reducing as well the risk of mother-to-child transmission of HIV. 1, 2 We hypothesize that this outstanding improvement of life expectancy of women of childbearing age is positively associated with the increasing procreation desires and fertility rates observed after ART initiation in several settings. [3] [4] [5] However, safe motherhood needs are partially met for HIV-infected women, since for instance the access to family planning, antenatal, and postnatal care services of good quality are not fully available in most settings. [6] [7] [8] [9] [10] [11] Several studies have showed that fertility desire among childless HIV-affected couples, even if lower than in the general population, is high, especially among younger individuals. 12, 13 Indeed, the pregnancy rate among HIV-infected women increases significantly after ART initiation, and this increase seems proportional to the duration of ART exposure, independently of the use of contraceptive methods. [12] [13] [14] [15] The pregnancy occurrence among HIV-infected women remains a major clinical and public health concern for the following reasons. First, women starting ART for their own health during pregnancy present a higher risk of virological failure than women starting ART while not pregnant. 16 Moreover, HIV infection has been pointed out as a leading indirect cause of maternal death in sub-Saharan Africa, [17] [18] [19] [20] increasing the risk of several maternal complications positively associated with maternal death. 21, 22 Finally, the vertical risk of HIV transmission has not been eliminated yet, especially in lower income settings. This is primarily due to the failure to reach high levels of linkage and retention throughout the cascade of HIV services for all pregnant, delivering, and breastfeeding women. 23 In West Africa, although the roll out of ART over the last decade has been slower than elsewhere in the developing world, it has considerably contributed to the overall improvement of survival of HIV-infected women in a context of high fertility. Available information about reproductive health patterns and more specifically demographic trends of fertility among HIVinfected women on ART remains poor in this region however. In this context, the aim of this study was to estimate over a 10-year period the incidence of pregnancy after ART initiation on a large sample of ART-treated HIV-infected women of reproductive age, and to identify the associated factors of pregnancy occurrence after ART initiation in West Africa.
METHODS

The IeDEA West Africa Collaboration
The International epidemiological Database to Evaluate AIDS (IeDEA) initiative (http://www.iedea-hiv.org) is a consortium of leading clinicians and epidemiologists launched in 2006 that has been addressing high-priority research questions and streamline HIV/AIDS research through large pooled regional databases. Its African organization was extensively described elsewhere. 24 This cohort analysis was conducted within the IeDEA West Africa Collaboration (http://mereva. isped.u-bordeaux2.fr/iedea/Accueil.aspx). Fifteen HIV/AIDS adult clinics located within 8 countries participated in this report: Benin (n = 1), Burkina Faso (n = 2), Côte d'Ivoire (n = 5), Gambia (n = 1), Guinea-Bissau (n = 1), Mali (n = 2), Nigeria (n = 2), and Senegal (n = 1). Every 18 months, each cohort submits information to the central coordinating center based in Côte d'Ivoire, using a standardized data format. The data collected capture demographic, clinical, biological, and therapeutic information at baseline and during follow-up visits.
Inclusion/Exclusion Criteria and Study Sample
We conducted a retrospective analysis within the West African cohort database among all HIV-infected women of reproductive age (,50 years) and starting ART for their own health between January 1998 and December 2011 according to in-country ART protocols. Women not reporting any follow-up visit were not retained for this analysis. Additionally, 1 clinic participating to the consortium was not systematically reporting pregnancies within its database and was therefore excluded from this analysis. As we were interested in estimating the incidence of pregnancy after ART initiation, HIV-infected women starting ART for their own health while pregnant were included for this analysis but were left censored 9 months after ART initiation (any prevalent pregnancy that initiated before ART initiation was thus not taken into account). The flow diagram of patients' selection is detailed in Figure 1 .
Data Collection and Outcome Definition
All eligible women started ART for their own health fulfilling clinical eligibility criteria established by in-country ART protocols. All of the participating clinics had the capacity to perform CD4 cell counts, hematology, and biochemistry. ART was provided free of charge by the national treatment programs according to their individual treatment algorithms. After entry into care, women were typically followed every 6 months or were seen at in-between visits for any intercurrent illness. CD4 cell counts were measured every 6 months. Baseline CD4 was the measure performed at the time of ART initiation or in the previous 6 months. Women not seen at least 6 months without any transfer or death report were considered lost to follow-up.
Pregnancy diagnosis was considered based on the delay of the last menstruation period according to the woman self- report that was assessed at each follow-up visit. The main outcome measure for this analysis was ever becoming pregnant after ART initiation, as reported in the database.
Statistical Analysis
Baseline characteristics were described and compared between pregnant and nonpregnant women using x 2 test for categorical and qualitative variables and Kruskal-Wallis nonparametric test for continuous variables. Incidence rates of pregnancy event including recurrences were calculated per 100 women-years of follow-up with their 95% confidence interval (CI). Poisson regression method was used to estimate incident rate of first pregnancy among women of reproductive age starting ART as soon as January 15, 1998, until end point date set at December 31, 2011. Each woman included contributed to the denominator from time of ART initiation to their date of pregnancy recording, their last visit or December 31, 2011. Women were right censored at the time of death or loss to follow-up when these events occurred.
Considering pregnancy as a time-dependent event, the probability of becoming pregnant according to the age at ART initiation was estimated using Kaplan-Meier analysis. To identify associated factors of the first pregnancy occurrence after ART initiation, we ran univariable and multivariable Poisson regression models performed with a manual backward selection method, assuming significant all associations with P values ,0.05. Maternal age was computed as a time-dependent variable in Poisson regression models. ART history (pretreated or naive) was considered as an explanatory variable. Statistical analyses were generated using SAS software (version 9.2 for Windows, Copyright 2013 for SAS Institute, Inc, Cary, NC).
RESULTS
Overall, 29,425 HIV-infected women accounted for the present analysis, contributing a total of 84,870 women-years of follow-up with 4.4% of death and 25.6% of loss to followup across the study period.
Baseline characteristics according to pregnancy experience are detailed in Table 1 . Women who reported a pregnancy were significantly younger at ART initiation than those who never reported such an event: 29.7 years in median versus 33.5 years (P , 0.001). Similarly, women who were identified as pregnant started ART at higher median CD4 cell count level (191 cells/mm 3 ) than those who never reported a pregnancy during the study period (172 cells/mm 3 ) (P , 0.001). Pregnancy was less frequent among women who started ART with a clinical stage III/IV or AIDS compared with those starting ART with a less-advanced stage of HIV disease (19.6% vs. 24.5%) (P , 0.001). Hemoglobin level at baseline among women becoming pregnant after ART initiation was slightly higher in median than among those who never became pregnant (10.2 vs. 10.1 g/dL; P = 0.01).
Pregnancy Occurrence
As detailed in Table 2 , 2515 pregnancies were reported among 2304 women during the course of follow-up: 2107 women had 1 pregnancy, 183 had 2 pregnancies, and 14 women reported 3 pregnancies. The crude incidence rate of pregnancy was 2.96 pregnancies per 100 women-years (95% CI: 2.85 to 3.08) ( Table 2 ). The highest rate was reported in Burkina-Faso (3.46 pregnancies per 100 women-years; 95% CI: 3.11 to 3.81), followed by Nigeria (3.43 pregnancies per 100 women-years; 95% CI: 3.19 to 3.66) and Togo (3.35 pregnancies per 100 women-years; 95% CI: 2.57-4.13). For the remaining 5 countries, the incidence rate of pregnancy was below 3.0 pregnancies per 100 women-years.
Median time from ART initiation to the first pregnancy was 24.6 months [interquartile range (IQR), 12.1-43.1]. Among women reporting several pregnancies, the median time between first pregnancy and the second one was 19.7 months (IQR, 13.1-30.3) and 15.3 months (IQR, 14.1-22.1) between the second and the third ones.
As shown also in Table 2 , the incidence rate of first pregnancy was 2.85 per 100 women-years (95% CI: 2.74 to 2.97) during the first 12 months after ART initiation and was increasing thereafter. The incidence rate of pregnancy was higher than 4 pregnancies per 100 women-years among women aged between 20 and 34 years, especially among those aged between 25 and 29 years peaking at 4.69 pregnancies per 100 women-years (95% CI: 4.32 to 5.06). For age groups 35-39 years old and 16-19 years old, incidence rate of pregnancy was of 2.74 (95% CI: 2.50 to 2.97) and 1.95 (95% CI: 0.60 to 3.30) pregnancies per 100 women-years, respectively. The lowest incidence rate of pregnancy was estimated in the age group of 40-49 years old [0.53 pregnancies per 100 women-years (95% CI: 0.43 to 0.62)].
As shown in Figure 2 , the overall pregnancy probability was 11% by the fourth year on ART; between 19% and 33% among women aged ,30 years at ART initiation, around 18% among women aged 30-35 years, and much lower in older women.
As presented in Table 2 , incidence rate of first pregnancy after ART initiation among women starting ART with a clinical stage A, B/I, II was 3.20 per 100 women-year (95% CI: 3.04 to 3.35), whereas this figure was lower among women starting ART at more advanced stages of HIV disease. Similarly, the incidence rate of first pregnancy among women starting ART with CD4 cells counts of $500 cells per cubic millimeter was 3.72 per 100 women-years (95% CI: 3.05 to 4.38) and decreased proportionally to the severity of immune deficiency at ART initiation. Although not statistically significant, pregnancy tended to be less frequent among women starting ART with lower levels of hemoglobin (Table 2) .
Factors Associated With Pregnancy Occurrence
The following factors collected at ART initiation and during follow-up were investigated in multivariable regression analysis to estimate adjusted incidence risk ratios (aIRRs) of the first pregnancy: country, year of starting ART, age (timedependent variable), clinical stage, baseline CD4 cell count, ART regimen, history of ART, and hemoglobin (Table 3) .
When compared with women aged 40-49 years, women aged 16-19, 20-24, 25-29, 30-34 , and 35-39 years had an increased risk of becoming pregnant after ART initiation (aIRR of 3.52, 7.12, 8.26, 7.64, and 5.11, respectively, P , 0.001).
Starting ART at an advanced clinical stage of HIV disease (CDC stage C or WHO stages III and IV) reduced significantly the likelihood of pregnancy after ART initiation (aIRR: 0.83; 95% CI: 0.74 to 0.93). CD4 cell count at ART initiation discriminated well the risk of first pregnancy after ART initiation: the higher the CD4 count at ART initiation, the more frequent the subsequent occurrence of pregnancy. Indeed, compared with women starting ART with a CD4 cell count less than 50 cells per cubic millimeter, the aIRR of pregnancy post-ART initiation was 1.14 (95% CI: 0.93 to 1.39), 1. 
DISCUSSION
This study estimated the occurrence of pregnancy among HIV-infected women after ART initiation at 15 clinical sites in 8 West African countries over a 10-year period. To explain demographic trends of the incidence of pregnancy in this population, we looked as well for epidemiological, clinical, biological, and therapeutic characteristics. According to our findings, the average crude incidence rate of pregnancy after ART initiation was 2.9 pregnancies per 100 women-years. To the best of our knowledge, it is the first time that such a figure is reported in this part of Africa known for its high-fertility patterns and infrequent use of contraceptive methods. Although elevated, the estimated pregnancy incidence we found in this population living with HIV and in care in West Africa was lower than among their uninfected counterparts in the region. Indeed, according to the 2012 African health observatory report, fertility rates across the countries we surveyed ranged between 4 and 6 live births per 1000 women-years. 25 Although this variation might be owed to methodological differences, it may also suggest that fertility patterns are somehow conditioned by HIV infection. Similarly, it seemed that the incidence rate of pregnancy within our study sample was lower than previous estimations in other sub-Saharan African settings. In Southern Africa, Bussmann et al 26 reported a post-ART pregnancy rate of 7.9 per 100 women-years in Botswana, and Westreich et al 15 reported an incidence rate of pregnancies of 5.2 per 100 womenyears after ART initiation in a South African clinical cohort. Furthermore, in rural Uganda, the incidence rate of pregnancy was as high as 9.5 per 100 women-years 24 months after ART initiation. 13 Finally, a larger study conducted by Myer et al reported an overall crude incidence rate of pregnancy after ART initiation of 9.0 per 100 women-years in 7 African countries including Côte d'Ivoire. Although not fully detailed, Myers et al estimation for Côte d'Ivoire appeared higher than the one we found in our study. We suspect that this difference might be owed to the fact that their study was conducted within a network of women-centered clinics focusing on PMTCT of HIV infection, thus, pregnancy was the main outcome measure with probably more accurate and rigorous detection methods. 14 We also suspect that differences in occurrence of pregnancy after ART initiation between West Africa and other African settings might be due to sociodemographic specificities and HIV disease and care patterns. Methodological variations across studies cannot however be fully excluded. Although systematically confirmed clinically, estimations on incidence rate of pregnancy presented in our study were initially based on women self-report of the last menstruation period. Bearing in mind that miscarriages and abortions are very frequent during the early months of pregnancy 27 and HIV infection has been pointed out as an important cause, 28 we suspect that a substantial number of pregnancies may have gone undetected. The former and the significant proportion of dropouts contributed clearly to an underestimation of the pregnancy incidence reported. Similarly, in this context of large-scale public health program, the data quality did not allow to document how patients break in care in a standardized way across sites. Finally, the lack of information on some potentially important confounding variables (such as marital status, parity, or family planning methods availability or use) limits somewhat the interpretation of our findings.
The incidence rate of pregnancy after ART initiation increased slightly but progressively throughout years in care, suggesting a positive effect of ART on fertility among women of reproductive age, and this association was particularly strong among younger women. This phenomenon is consistent with studies conducted in other sub-Saharan African settings, showing an increased cumulative incidence rate of pregnancy post-ART initiation proportional to time on clinical follow-up. 14, 15, 26 This finding suggests that the global restoration of health status favored by ART and measured by CD4 cell recovery also boosted fertility functions among women of reproductive age. It is also possible that immune restoration owed to ART favored the onset of maternal fetus tolerance mechanism increasing the probability to take a pregnancy to term successfully. However, such a biological association between post-ART health improvement and restoration of fertility functions requires further research to better understand the underlying biological mechanisms and their association with temporal changes in couple and family life experiences. Additionally, our findings show that both age and clinical/immunological parameters at ART initiation were important predictors of reproductive patterns among HIVinfected women in care. Consistently with other studies, the incidence rate ratio of pregnancy after ART initiation was significantly higher among younger and healthier HIVinfected women than among their older counterparts with a poorer health status. [13] [14] [15] However, the increase of the incidence rate of pregnancy after ART initiation reached its peak at 25-29 years old to decrease progressively afterward, suggesting that although ART might have a positive effect on fertility, it remains restricted to biological conditions, respecting human reproductive cycle.
Healthier women at ART initiation were those having the highest probability of becoming pregnant. This association is explained by the fact that their improved health status increases their reproductive ability but also by the fact that an early exposure to ART might limit the HIV-associated risk of miscarriage. This increased incidence risk of pregnancy associated to higher CD4 levels at ART initiation should be better taken into account in strategies such as treatment as prevention promoting universal and early treatment initiation regardless of CD4 levels.
Unintended pregnancy rates are high in sub-Saharan Africa among women of reproductive age and raise major public health concerns among younger women in these settings. 29 We hypothesize that besides the potential benefits of ART on restoring fertility functions, an important number of these pregnancies is owed to the limited capacity of HIVinfected women to manage their procreation desires. Indeed, the unmet needs for family planning among West African women irrespective of their HIV status are as high as 30%. 9, 30 It has been pointed out that integrating family planning services into HIV care is an important shortcoming to reduce unintended pregnancy rates among HIV-infected women and eliminate the vertical risk of HIV transmission. 1, 31, 32 To conclude, this is one of the first studies estimating incidence rate of pregnancy among a large regional cohort of about 30,000 HIV-infected women initiating ART for their own health and accounting for about 75,000 women-years of follow-up across 8 West African countries. Although lower than in other African settings and probably underestimated, the incidence rate of pregnancy increases proportionally after ART initiation in West Africa. Moreover, pregnancy after ART initiation remains an event, particularly for younger women, with potentially important individual and public health consequences. As universal access to ART has enabled HIV-infected women of reproductive age to live longer and with higher quality of life standards, childbearing is a growing desire among this population. Understanding the dynamics of fertility among women on ART is a key step to correctly fit the strategies of integrating family planning into HIV care and to help HIV-infected women to correctly fulfill their procreation trajectory through safe and adapted motherhoods programs. This is one of the many challenges that HIV care and treatment programs must address upfront now, especially in West Africa.
